New Pfizer Shingles Vaccine Study

Brief description of study

While there is an existing Shingles vaccine, it is not 100% effective and it is not widely available in many countries because it is costly and time-consuming to produce. Given the success of the mRNA COVID-19 vaccine, we have a new Shingles vaccine candidate that uses the same technology.

Before vaccines can be mass produced for the general public, their safety, tolerance, and efficacy are tested in clinical trials. This study will test different mRNA Shingles vaccines versus the regular vaccine. You will be asked to provide samples of blood so that can see how your immune system responded.

You may be asked to complete up to 13 visits in Manhattan over an 8 month period, with the possibility of a 5 year extension with an additional 5 visits.

All participants will be reimbursed for each study visit.

This study is sponsored by Pfizer.


Clinical Study Identifier: s22-01217
ClinicalTrials.gov Identifier: NCT05703607
Principal Investigator: Angelica Cifuentes Kottkamp.
Other Investigators: Lalitha Parameswaran, Ellie R. Carmody, Sean P. Heffron, Tamia Davis, Mark J. Mulligan.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.